

ASX release

4 October 2023

Changes to executive leadership team

Medibank has today announced changes to its executive leadership team. Felicia Trewin will be appointed Group Lead – Data & Technology and Robert Read will be appointed Group Lead – Amplar Health. The latter follows Dr Andrew Wilson’s decision to step back from the executive leadership team and take on the role of Group Chief Medical Officer in a part time capacity.

Medibank CEO David Koczkar said:

“I am excited to be welcoming Felicia and Rob to the executive leadership team. Together we are well positioned to grow and to deliver on our 2030 vision to achieve the best health and wellbeing for Australia.

“Felicia brings with her significant experience in technology, large program delivery, security and transformation in financial services.

“Rob joined Medibank last year and has broad experience in health including delivering customer led strategies, driving business growth and operational management.

“Together Felicia and Rob will be instrumental in helping us continue to deliver for our customers.

“I am also very pleased Andrew will continue to contribute to our company after making the decision to step back from the executive leadership team after 13 years and take on the role of our Group Chief Medical Officer.

“Andrew has been fundamental in our transformation to a health company. I would like to thank Andrew for his contribution to Medibank and am personally looking forward to continuing to work with him in his new role as Group Chief Medical Officer.”

Group Lead – Data & Technology

As Group Lead – Data & Technology, Felicia will have a dedicated focus on technology, security, data management and our core platforms.

Felicia has been Chief Technology Officer at AMP since March 2022. She has more than 25 years of experience in technology including having been the CIO at AustralianSuper, and having previously worked at ANZ, Deloitte, Microsoft and Accenture.

Felicia will begin in the role in early 2024 with Kylie Williamson continuing to act in the role until that time.

Group Lead – Amplar Health

As Group Lead – Amplar Health, Rob will be responsible for Medibank’s growing role as a health services provider. This includes responsibility for the health services we deliver on behalf of our PHI business and external customers in the private and public sector, including telehealth, in-home care, and our healthcare investments.

Rob joined Medibank in June 2022 as Amplar Health Chief Commercial Officer. In this role he has been responsible for evolving the health services strategy including our focus on virtual health and growing our prevention services. Prior to that, Rob was CEO and MD at MedAdvisor Ltd and has also held senior roles at GSK PLC and as an investor in both venture capital and private equity.

Rob will begin in the role on 13 November 2023 with a transition period with Andrew.

Group Chief Medical Officer

As Group Chief Medical Officer, Andrew will be responsible for clinical oversight across the business as we look to support the triple aim of health: better outcomes, better affordability and better experiences.

Andrew has 25 years of experience in the health system and remains a practising clinician and lecturer. Andrew will continue to represent Medibank on a number of our investment Boards.

Andrew will transition to the role of Group Chief Medical Officer and will carry out the role on a part time basis. Andrew will report to CEO David Koczkar in his new role.

As a result of these changes, the executive leadership team will comprise:

Chief Executive Officer, David Koczkar

Group Lead – People, Spaces & Sustainability, Kylie Bishop

Group Lead – Digital & Ventures, Rob Deeming

Group Lead – Chief Customer Officer, Milosh Milisavljevic

Group Lead – Trust, Legal & Compliance, Group General Counsel and Company Secretary, Mei Ramsay

Group Lead – Amplar Health, Robert Read

Group Lead – Chief Financial Officer & Group Strategy, Mark Rogers

Group Lead – Policy, Advocacy & Reputation, Meaghan Telford

Group Lead – Data & Technology, Felicia Trewin

This announcement has been authorised for release by the CEO.

For further information please contact:

For media

Juliet Williams

Corporate Communications Manager

M: +61 437 931 918

Email: Juliet.Williams@medibank.com.au

For investors/analysts

Michael Hajdinjak

Hub Lead - Investor Relations

M: +61 475 038 762

Email: investor.relations@medibank.com.au